VNDA
Vanda Pharmaceuticals Inc
NASDAQ · Biotechnology
$7.57
+0.34 (+4.70%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 211.70M | 234.07M | 134.97M | 122.09M | 118.94M |
| Net Income | -20,127,370 | -20,029,448 | 17.72M | 12.67M | 12.10M |
| EPS | — | — | — | — | — |
| Profit Margin | -9.5% | -9.0% | 13.1% | 10.4% | 10.2% |
| Rev Growth | -9.6% | -9.6% | -3.5% | +22.8% | +0.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 2.14M | 2.14M | 164.99M | 139.11M | 164.30M |
| Total Equity | 232.27M | 232.27M | 285.01M | 288.85M | 284.24M |
| D/E Ratio | 0.01 | 0.01 | 0.58 | 0.48 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -16,665,462 | -17,505,737 | 23.46M | 21.61M | 18.83M |
| Free Cash Flow | — | — | 19.80M | 20.08M | 12.24M |